OptimizeRx announced OptimizeRx’s CEO Will Febbo is invited to speak at the upcoming J.P. Morgan Healthcare Conference. Ahead of the conference, OPRX is providing the following business update and key industry trends from management’s presentation. "Our key strengths which we expect will propel OPRX in 2023 include: Our network reach of more than 60% of active prescribers; Continued expansion of omnichannel communication capabilities to build cutting edge solutions; Staying at the leading-edge of connecting touchpoints to both healthcare providers and patients; AI-enablement which identifies HCPs whose patients are most in need of our customers’ resources and therapies. In the new year, we remain committed to leveraging innovation to improve patient journeys and outcomes through the intelligent convergence of healthcare data and technology across the OptimizeRx platform…. We will continue to be the leader in advancing the application of AI driven by RWE for the purposes of predicting the healthcare resource and therapy needs of HCPs and patients. We are setting a new standard for unparalleled ROI and improved patient outcomes. At the heart of this success through innovation, our AI/RWE business pipeline remains strong, and we continue our work with the biggest pharma brands in the industry through existing, extended, and new deals… Our POC messaging includes delivery of cost-saving resources to help make therapies affordable, something we have always done, and continue to do well; it is now even more effective with the application of RWE to find the most appropriate healthcare provider targets. Additionally, we have proven out the new standard for ROI and patient outcomes through finding unique patients best suited for novel therapies… In 2023, we will further demonstrate our ability to integrate our products and solutions with business enterprises with a greater shift away from tactical to solution-based selling, of which our AI/RWE deals are illustrating. In doing so, we are cementing scalable tech partnerships with our clients and strengthening our path forward to profitability."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on OPRX:
